Find a Physician

Email this profile
Portrait View Larger

Anupama Narla

Academic Appointments

  • Assistant Professor of Pediatrics (Hematology/Oncology) at the Lucile Salter Packard Children's Hospital

Key Documents

Contact Information

  • Clinical Offices
    Pediatric Hematology/Oncology 1000 Welch Rd Ste 300 MC 5798 Palo Alto, CA 94304
    Tel Work (650) 723-5535 Fax (650) 723-5231
  • Academic Offices
    Personal Information
    Not for medical emergencies or patient use

Professional Overview

Clinical Focus

  • Pediatric Hematology-Oncology

Academic Appointments

Administrative Appointments

  • Director of Hematology Education, Children's Hospital Boston (2010 - 2012)
  • Chief Fellow, Children's Hospital Boston (2008 - 2009)

Boards, Advisory Committees, Professional Organizations

  • Scientific Committee Member, American Society of Hematology (2013 - present)
  • Member, North American Pediatric Aplastic Anemia Consortium (2013 - present)
  • Member, American Society of Hematology (2006 - present)
  • Member, American Society of Pediatric Hematology/Oncology (2006 - present)

Professional Education

Board Certification: Pediatrics, American Board of Pediatrics (2006)
Board Certification: Pediatric Hematology-Oncology, American Board of Pediatrics (2011)
Fellowship: Children's Hospital Boston MA (2009)
Residency: UCSF-Graduate Medical Education CA (2006)
Internship: UCSF-Graduate Medical Education CA (2004)
Medical Education: University of Pennsylvania Registrar's Office PA (2003)

Scientific Focus

Current Research and Scholarly Interests

More than a decade ago, researchers discovered that a rare congenital bone marrow failure syndrome, Diamond Blackfan anemia (DBA), is caused by mutations in a ribosomal protein RPS19. Subsequently, my mentor Dr. Benjamin Ebert identified RPS14 as the gene responsible for the profound macrocytic anemia in the 5q- syndrome, a subtype of myelodysplastic syndrome. This reinforced the connection between ribosomal abnormalities and defects in erythropoiesis. Moreover, mutations in other genes required for normal ribosome biogenesis have been implicated in other rare congenital syndromes including Schwachman-Diamond syndrome, X-linked dyskeratosis congenita, Cartilage Hair Hypoplasia and Treacher Collins syndrome. Each of these disorders is associated with specific defects in ribosome biogenesis, which cause distinct clinical phenotypes, most often involving bone marrow failure, and have become collectively known as ribosomopathies.

I have studied the molecular mechanisms by which ribosomal dysfunction leads to bone marrow failure by further characterizing the signaling pathways that are triggered and the subsequent effects on hematopoiesis. I published work on ribosomal haploinsufficiency causing selective activation of p53 in human erythroid progenitor cells and on the effects of a microRNA cooperating in the pathogenesis of the 5q- syndrome. I will continue to focus on understanding the effects of specific drugs on these disorders which may uncover further clues about pathophysiology and as importantly, will directly benefit patients. I have published work on the effects of dexamethasone and lenalidomide, the first line therapies for DBA and 5q- MDS respectively, on erythropoiesis and am an author on a manuscript examining the effects of leucine, a stimulator of the mTOR pathway, in these disorders.

The goal of my lab is to make meaningful contributions to the elucidation of the pathophysiology of ribosomopathies, the development of novel therapies and the care of patients in the field.


Publication tag cloud

Publication Topics

View All 17

Stanford Medicine Resources:

Footer Links: